You are here

Acenta Discovery, Inc.

Company Information
Address
Acenta Discovery, Inc. 9030 South Rita Road
Tucson, AZ 85747
United States



Information

UEI: N/A

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Development of NET-Selective Piperidine-Based PET Ligand

    Amount: $499,986.00

    DESCRIPTION (provided by applicant): World-wide public health surveys point to an increasing global health burden resulting from serious brain disorders, particularly mood-related disorders such as de ...

    STTRPhase I2005Department of Health and Human Services National Institutes of Health
  2. Development of NET-Selective Piperidine-Based PET Ligand

    Amount: $499,986.00

    DESCRIPTION (provided by applicant): World-wide public health surveys point to an increasing global health burden resulting from serious brain disorders, particularly mood-related disorders such as de ...

    SBIRPhase I2005Department of Health and Human Services National Institutes of Health
  3. Akt Inhibitors to Treat Ewing's Sarcoma

    Amount: $596,620.00

    DESCRIPTION (provided by applicant): Novel drugs that improve overall survival with decreased morbidity are critical in the war on cancer. Acenta Discovery Inc. has partnered with the Toretsky Lab o ...

    STTRPhase I2004Department of Health and Human Services National Institutes of Health
  4. Caspase Inhibitor for Neuroprotection

    Amount: $348,523.00

    DESCRIPTION (provided by applicant): An important role for apoptosis has been established in various pathological processes, particularly in nervous tissues. Apoptosis essentially contributes to neuro ...

    STTRPhase I2004Department of Health and Human Services National Institutes of Health
  5. Akt Inhibitors to Treat Ewing's Sarcoma

    Amount: $596,620.00

    DESCRIPTION (provided by applicant): Novel drugs that improve overall survival with decreased morbidity are critical in the war on cancer. Acenta Discovery Inc. has partnered with the Toretsky Lab o ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
  6. Caspase Inhibitor for Neuroprotection

    Amount: $348,523.00

    DESCRIPTION (provided by applicant): An important role for apoptosis has been established in various pathological processes, particularly in nervous tissues. Apoptosis essentially contributes to neuro ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
  7. NET- Selective Ligands for the Treatment of Depression

    Amount: $545,039.00

    DESCRIPTION (provided by applicant): World-wide public health surveys point to an increased global health burden for serious psychiatric disorders, particularly depression. Indeed, by 2020 it is ex ...

    STTRPhase I2003Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government